Evolving Use of ICIs and Targeted Tx in NSCLC and SCLC

News
Video

In this video, Apar Ganti, MD, highlights recent advances and studies presented at ASCO 2018 on management of NSCLC and SCLC with ICIs and targeted agents.

In this video, Apar Ganti, MD, highlights recent advances and studies presented at ASCO 2018 on management of NSCLC and SCLC with ICIs and targeted agents.

Recent Videos
Trials at scale can be conducted in middle-income, low-middle-income, and even lower-income countries if you organize a trial ecosystem.
For example, you have a belt of certain diseases or genetic disorders that you come across, such as sickle cell disease or thalassemia, that are more prevalent in these areas.
Talent shortages in the manufacturing and administration of cellular therapies are problems that must be addressed at the level of each country.
Point-of-care manufacturing, scalable manufacturing, and bringing the cost down [can help].
A novel cancer database may assist patients determine what clinical trials they are eligible to enroll on and identify the next best steps for treatment.
A consolidated database may allow providers to access information on a patient’s prior treatments and genetic abnormalities all in 1 place.
A study presented at ASTRO 2025 evaluated the feasibility of using a unified cancer database to consolidate information gathered across 14 institutions.
Co-hosts Kristie L. Kahl and Andrew Svonavec highlight what to look forward to at the 2025 ESMO Annual Congress, from hot topics and emerging trends to travel recommendations.
Physical therapists may play a key role in patient care before, during, and after treatment for cancer, according to Alison Ankiewicz, PT, DPT.
Related Content